Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lupin Launches Generic Cymbalta | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Lupin Launches Generic Cymbalta

Lilly sees expected generic competition for CNS drug

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Lupin Pharmaceuticals, Inc., the U.S. subsidiary of Pharma Major Lupin Limited, has launched Duloxetine Hydrochloride Delayed-release (HCl DR) Capsules 20 mg, 30 mg and 60 mg strengths. The company received final approval to market its Duloxetine HCl DR Capsules USP, 20 mg, 30 mg, 40 mg and 60 mg strengths from the FDA yesterday.

Lupin’s Duloxetine HCl DR Capsules are the generic equivalent of Lilly‘s Cymbalta Delayed-release Capsules at those same dosages. Duloxetine HCl DR Capsules are indicated for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD) and management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics